The PERT Consortium

What The PERT Consortium does

The PERT Consortium is a 501(c)(3) nonprofit healthcare organization headquartered in Nashua, New Hampshire, founded in 2015 by a group of physicians at Massachusetts General Hospital. Its mission is to establish, optimize, and expand multidisciplinary Pulmonary Embolism Response Teams (PERT) for the quality care of PE patients. The organization operates an interconnected portfolio of programs: a multi-center Pulmonary Embolism Quality Assurance Database with 6,800+ patients across 30+ US institutions, the PERC (Pulmonary Embolism Research Collaborative) initiative for data standardization, the PE Centers of Excellence accreditation program with Regional and Comprehensive designations, and the newly launched PRISM three-year program targeting 100 accredited sites worldwide. It also co-sponsors clinical trials with industry partners, including the STORM-PE trial with Penumbra, the HI-PEITHO trial with Boston Scientific (results published in NEJM), and the APEX-AV study with AngioDynamics.

The consortium's product surface spans research infrastructure, accreditation, education, and international collaboration. Educational channels include the Annual Pulmonary Embolism Scientific Symposium, CME Dinner Series across eight US cities, PERTCast podcast, webinars, PERTinent Updates newsletter, and the Trainee Council. International affiliates span the UAE, Greece, Australia, Spain, Dominican Republic, Ukraine, Saudi Arabia, and Singapore, with the BPA-CTEPH Alliance extending scope into chronic thromboembolic pulmonary hypertension. The organization is led by Founder Dr. Kenneth Rosenfield, with Dr. Richard N. Channick (UCLA) recognized as a co-founder and past president, John M. Moriarty and Brent Keeling referenced as current presidents, and Rachel Rosovsky (MGH) as President-Elect.

The revenue model is a hybrid of corporate memberships, program fees, and donations. Corporate members are organized into Platinum (Penumbra), Gold (AngioDynamics, Boston Scientific, Inari, Thrombolex), Silver (Argon, BMS Pfizer, Imperative Care), and PE Startup tiers, with international affiliates, tax-deductible donations, $2,500 COE application fees, and Annual Symposium registration fees as additional streams. PRISM introduces a multi-year contract structure with re-accreditation fee waivers tied to data commitment. The organization has no parent company, no private equity or venture capital ownership, and no publicly disclosed revenue or financial statements.

Name

The PERT Consortium

Legal name

The National Pulmonary Embolism Response Team Consortium

Website

https://pertconsortium.org

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

The PERT Consortium is a 501(c)(3) nonprofit healthcare organization that supports pulmonary embolism response teams through research, education, and quality improvement, serving hospitals and clinicians in the US and internationally through accreditation, clinical trials, and a multi-center patient registry.

Ownership category

akta.pro rank

Product category

Medical Professional Association / Healthcare Research Nonprofit

NAICS

Professional Organizations (813920)

SIC

Services-Health Services (8000)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Pulmonary embolism research
• Medical professional society
• Healthcare accreditation services
• Clinical trial consortium
• Continuing medical education

Headquarters

HQ city

Nashua

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Corporate Memberships: The organization receives funding from corporate members at various sponsorship levels: Platinum (Penumbra), Gold (AngioDynamics, Boston Scientific, Inari, Thrombolex), Silver (Argon, BMS Pfizer, Imperative Care), and PE Startups (Akura, Cyclomedica, Endovascular Engineering, Innova Vascular, Inquis Medical).
2. Donations: As a 501(c)(3) nonprofit organization, The PERT Consortium accepts tax-deductible donations from individuals and organizations to support its mission.
3. Center of Excellence Accreditation Fees: Institutions pay application fees ($2,500 non-refundable) and accreditation fees for the COE certification program.
4. Event Registration Fees: The organization holds an Annual Pulmonary Embolism Scientific Symposium with registration fees. International members receive complimentary registration benefits.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

The PERT Consortium is a 501(c)(3) nonprofit organization that establishes, optimizes, and expands multidisciplinary Pulmonary Embolism Response Teams (PERT) for the quality care of pulmonary embolism patients. It delivers value through a multi-center Quality Assurance Database, clinical research trials, Center of Excellence accreditation, the PRISM quality improvement program, international affiliations, and continuing medical education events and resources.

Product overview

The PERT Consortium is a 501(c)(3) nonprofit organization serving as the premier organization dedicated to establishing, optimizing, and expanding multidisciplinary Pulmonary Embolism Response Teams (PERT). Their portfolio consists of multiple interconnected programs: the core PERC (Pulmonary Embolism Research Collaborative) Quality Assurance Database for data collection and outcomes research; the PRISM accreditation program for unifying hospitals worldwide; PE Centers of Excellence certification for recognizing institutional excellence; research initiatives including STORM-PE Trial, HI-PEITHO Trial, and APEX-AV Study conducted with industry partners; educational resources including Annual Symposium, CME Dinner Series, Webinars, PERTCast podcast, and Grand Round Requests; and patient education materials including the Transitions of Care program. Additional programs include the BPA-CTEPH Alliance, Trainee Council for professional development, PERT International for global affiliations, and the Founder's Fund award program.

Differentiator

Problem solved

Functional benefit

Brands

• PERC™ (Pulmonary Embolism Research Collaborative): A new initiative gathering experts and stakeholders involved with management of patients with acute pulmonary embolism, focused on defining and developing consensus about components of clinical care and outcomes.
• PRISM
• BPA-CTEPH Alliance
• PERT Cast

Products and services

• Pulmonary Embolism Quality Assurance Database (PERT Registry) Multi-center database of patient-level data from patients admitted with PE for whom the PERT team has been consulted, used for epidemiologic, therapeutic, quality assessment, and outcomes research by participating healthcare institutions.
• PERC (Pulmonary Embolism Research Collaborative) Research initiative gathering experts and stakeholders to define consensus on clinical care components and outcomes, standardizing data collection to establish an expanding evidence base for acute PE care.
• PRISM Accreditation and Quality Improvement Program Transformative three-year program (limited to 100 sites) that unifies hospitals worldwide to provide consistent advanced PE care, integrating accreditation with ongoing data-driven quality improvement.
• PE Centers of Excellence (COE) Accreditation Accreditation program recognizing institutions demonstrating excellence in PE care through rigorous criteria encompassing medical research, innovative treatment methodologies, and patient-centered care, with Regional and Comprehensive designations.
• BPA-CTEPH Alliance Alliance fostering collaboration among practitioners and researchers in balloon pulmonary angioplasty (BPA) and chronic thromboembolic pulmonary hypertension (CTEPH), advancing understanding through education and shared expertise.
• Trainee Council Multidisciplinary platform for trainees (fellows, residents, medical students) to collaborate and inform the consortium on career development issues within VTE, planning educational events including the Annual Meeting and Physicians in Training Bootcamp.
• PERT International Affiliation Program Global institutional affiliation program offering resources, educational opportunities, and a collaborative platform for advancing PE care worldwide, with affiliated hospitals in the UAE, Greece, Australia, Spain, Dominican Republic, Ukraine, Saudi Arabia, and Singapore.
• STORM-PE Clinical Trial Prospective multi-center randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Indigo Mechanical Aspiration for treatment of Intermediate High Risk PE, partnered with Penumbra. Results demonstrated CAVT achieved 2.7x larger thrombus burden reduction.
• HI-PEITHO Clinical Trial Landmark randomized trial (N=544) determining whether ultrasound-facilitated catheter-directed thrombolysis (USCDT) via EKOS Endovascular System plus anticoagulation improves outcomes versus anticoagulation alone in acute intermediate-risk PE, partnered with Boston Scientific. Results published in NEJM.
• APEX-AV Clinical Study Investigational Device Exemption study supporting AlphaVac F1885 PE System indication for treatment of Pulmonary Embolism, enrolling up to 122 patients at up to 20 U.S. sites, partnered with AngioDynamics.
• Annual Pulmonary Embolism Scientific Symposium Annual multidisciplinary scientific symposium bringing together PE care specialists, clinicians, scientists, administrators, and industry professionals to share knowledge and pursue advancements in PE patient care. The 11th Annual Symposium was held September 17-20, 2025 in San Diego, CA.
• CME Dinner Series Continuing medical education dinner series hosted in cities including Tampa, Dallas, NYC, Chicago, San Diego, Las Vegas, Atlanta, and Orlando for healthcare professionals focused on PE care and treatment.
• Founder's Fund Award Program Endowed fund featuring the Dr. Kenneth Rosenfield Founder's Award and Keynote Lectureship recognizing exceptional contributions to Pulmonary Embolism care.

Quantifiable outcome

• Over 6,800 patients in quality assurance database across 30+ institutions
• +2 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered platinum member, gold member, content partner, silver member, research partner and regulatory partner.

• Penumbra, Inc.platinum memberStrategic or Co-development PartnerPenumbra is a Platinum corporate member and clinical trial partner. The PERT Consortium partnered with Penumbra on the landmark STORM-PE randomized controlled trial evaluating Indigo Mechanical Aspiration for intermediate-high risk PE treatment. The trial demonstrated CAVT achieved 2.7x larger thrombus burden reduction vs anticoagulation alone.
• Boston Scientific Corporationgold memberStrategic or Co-development PartnerBoston Scientific is a Gold corporate member and joint research partner on the HI-PEITHO trial (N=544), evaluating EKOS ultrasound-facilitated catheter-directed thrombolysis. Results published in NEJM showed EKOS demonstrated superiority to anticoagulation alone for intermediate-risk PE.
• AngioDynamics, Inc.gold memberStrategic or Co-development PartnerAngioDynamics is a Gold corporate member and partner on the APEX-AV (AlphaVac) study investigating the AlphaVac F1885 PE System for pulmonary embolism treatment. The PERT Consortium also launched the ALPHA-PE Research Fund in 2026 supporting independent PE research with awards of $50,000 to $750,000.
• Janssen Pharmaceuticals, Inc.content partnerGTM or Marketing PartnerJanssen partnered with The PERT Consortium to co-develop patient education content on DVT and PE including videos, PDFs in English and Spanish, and a Transitions of Care podcast series featuring PERT physicians.
• Inari Medicalgold memberTechnology or IntegrationInari Medical is a Gold corporate member supporting The PERT Consortium's mission to advance PE care.
• Thrombolexgold memberTechnology or IntegrationThrombolex is a Gold corporate member supporting The PERT Consortium's mission to advance PE care.
• Argon Medical Devicessilver memberTechnology or IntegrationArgon Medical Devices is a Silver corporate member supporting The PERT Consortium's mission.
• BMS Pfizersilver memberTechnology or IntegrationBMS Pfizer is a Silver corporate member supporting The PERT Consortium's mission.
• Imperative Caresilver memberTechnology or IntegrationImperative Care is a Silver corporate member supporting The PERT Consortium's mission.
• University Medical Center Mainzresearch partnerStrategic or Co-development PartnerUniversity Medical Center Mainz partnered with The PERT Consortium and Boston Scientific on the HI-PEITHO trial as the lead research institution.
• US FDAregulatory partnerStrategic or Co-development PartnerThe US FDA collaborated with The PERT Consortium on the inaugural PERC meeting held in Washington DC in April 2022, to establish consensus on data elements for acute PE.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• International Society on Thrombosis and Haemostasis (ISTH): ISTH is the leading global scientific society for thrombosis and haemostasis research, covering VTE including PE. It is comparable to PERT as a peer society focused on VTE/PE evidence generation, scientific meetings, and education, but operates globally with broader thrombosis scope rather than PE-response-team operational focus.
• American Heart Association (AHA): AHA is the largest US cardiovascular nonprofit with extensive research funding, guideline authority, and CME programs covering PE. It is comparable to PERT as a peer cardiovascular society but operates across the full cardiovascular disease spectrum rather than PE-specific response team development.
• American College of Chest Physicians (CHEST): CHEST is a major multidisciplinary medical society covering pulmonary, critical care, and sleep medicine, including VTE guidelines. It is comparable to PERT as a peer organization producing clinical guidelines and consensus statements on PE, but operates at much broader scope across all chest medicine rather than PE-specific.
• American Thoracic Society (ATS): ATS is the leading pulmonary and critical care medicine society with significant activity in PE/VTE research and clinical guidelines. It is comparable to PERT as a peer society addressing PE from the pulmonary medicine perspective, but covers all respiratory and critical care medicine rather than PE-specific response team models.
• European Society of Cardiology (ESC): ESC is the leading European cardiology society producing PE diagnosis and management guidelines used internationally. It is comparable to PERT as a peer cardiovascular authority with PE clinical guidelines, but operates with broader cardiology scope and a different geographic focus.
• American College of Cardiology (ACC): ACC is the leading cardiology professional society with significant guideline and registry activity in cardiovascular disease including PE management. It is comparable to PERT as a peer cardiology society, but serves all cardiology subspecialties rather than focusing on PE response teams.

Direct peers

• National Blood Clot Alliance (NBCA): NBCA is a US patient advocacy nonprofit focused on DVT and PE awareness, education, and prevention. It is directly comparable to PERT as a peer PE-focused nonprofit, though NBCA leads on patient advocacy while PERT leads on provider/clinician infrastructure and research.
• Society for Cardiovascular Angiography and Interventions (SCAI): SCAI is the interventional cardiology professional society directly involved in catheter-based PE intervention, with executive committees and publications on pulmonary embolism. It is highly comparable to PERT as a peer specialty society running PE quality programs and guidelines, with overlapping membership in interventional cardiology and PE catheter-directed therapy.
• Pulmonary Hypertension Association (PHA): PHA is a nonprofit organization dedicated to pulmonary hypertension, including CTEPH (chronic thromboembolic pulmonary hypertension) which is closely related to acute PE. PERT's BPA-CTEPH Alliance demonstrates direct programmatic overlap, making PHA a direct peer in adjacent VTE/CTEPH patient advocacy and education.

Emerging players

• Foundation for Venous and Lymphatic Disorders: FVLD is a nonprofit focused on venous and lymphatic disorders including VTE research, education, and advocacy. It is comparable to PERT as a peer organization addressing venous thromboembolism, but with broader venous scope and less PE-response-team operational focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/pertconsortium
• LinkedInlinkedin.com/company/pertconsortium

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The PERT Consortium